×

Open Monoclonal Technology Announces OmniAb(TM) Alliance With Five Prime

PALO ALTO, Calif., Oct. 05, 2015 (GLOBE NEWSWIRE) -- Open Monoclonal Technology, Inc. (OMT) today announced a license that provides Five Prime Therapeutics, Inc. (NASDAQ:FPRX) with access to OMT’s proprietary OmniRat®, OmniMouse® and OmniFlic™ human antibody generation platforms. Five Prime becomes OMT’s 16th corporate partner globally with such multi-platform access.

Dr. Roland Buelow, OMT’s founder and CEO, said, “Five Prime's large collection of medically relevant extracellular proteins combined with its sophisticated screening technology is particularly well suited for the identification of therapeutic human antibody targets. We are pleased to grant Five Prime access to OMT’s mono- and bi-specific antibody platforms and deep antibody repertoire sequencing technology for the generation of novel therapeutic candidates.”

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for the generation of human therapeutic antibodies, naturally optimized human antibodies®, and the only company in the world with four transgenic animal platforms, jointly known as OmniAb.

OmniRat® is the industry’s first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. OmniMouse® is a transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic is an engineered rat with a fixed light chain for development of bispecific, fully human antibodies. UniRat is the first transgenic rat generating fully human heavy chain-only antibodies and nanobodies for polyspecific applications.

All four OmniAb™ platforms deliver human antibodies with high affinity, specificity, expression, solubility and stability. They use patented technology, have broad freedom to operate and are available worldwide for all targets and indications.

Current partners include Amgen, Caltech, Celgene, Chugai, Five Prime, Genmab, Genentech, Gloria Pharmaceuticals, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, University of Nottingham and several undisclosed biotech and pharmaceutical companies. Animal hosting and OmniAb antibody discovery services are available via Antibody Solutions and Sage Labs in the US, Aldevron and Taconic Biosciences in Europe, and WuXi AppTec in China.

For more information, please visit www.omtinc.net or contact Brian Lundstrom at +1-775-420-7750 or bl@omtinc.net.


Source:Open Monoclonal Technology, Inc.